Original price was: $144.99.$134.99Current price is: $134.99.
This item has been third-party tested by accredited U.S. laboratories and confirmed to meet a minimum purity of 98% through rigorous verification standards.
Updated COA's
Secure Shipping Guaranteed
Verified for Purity
Original price was: $144.99.$134.99Current price is: $134.99.
Research Chemical products are third-party tested by MZ Biolabs, an independent laboratory based in Arizona. Each batch is analyzed to ensure accuracy, purity, and that all specifications are met.
Discover the groundbreaking potential of our CJC-1295 and Ipamorelin peptide combination for cutting-edge research in growth hormone modulation and cellular rejuvenation.
Fusing the unique properties of CJC-1295 DAC and Ipamorelin, our combination pack provides researchers with an unparalleled toolkit for their studies in growth hormone regulation and cellular rejuvenation. Rigorously synthesized to ensure maximum purity and potency, our peptides empower researchers to dive into complex biological processes with confidence and precision.
Experience the transformative synergy of CJC-1295 DAC and Ipamorelin peptides, unlocking new avenues of scientific exploration and innovation in growth hormone research.
Crafted to mimic the action of natural growth hormone-releasing hormone (GHRH), CJC-1295 DAC facilitates potent binding with growth hormone-releasing hormone receptors in the pituitary gland. With an extended half-life and fortified stability conferred by the Drug Affinity Complex (DAC), CJC-1295 DAC ensures sustained and reliable research, ideal for in-depth investigations into growth hormone dynamics and related research applications.
As a distinguished member of the Growth Hormone-Releasing Peptides (GHRP) family, Ipamorelin ignites research opportunities by stimulating the pituitary gland to release growth hormone. Its versatile action expands studies and research related to body fat management, skin elasticity enhancement, and energy level optimization, making it a crucial asset in diverse research pursuits.
By purchasing from ResearchChemical.com, you acknowledge and agree that you are acquiring Research Chemicals. These chemical substances are specifically designed for utilization in scientific and medical research endeavors.
It is essential to note that these research chemicals are intended exclusively for laboratory use. They are not sold for consumer use.
Please be advised that the statements made on this website have not been evaluated by the U.S. Food and Drug Administration (FDA). Furthermore, the products offered by this company are not intended to diagnose, treat, cure, or prevent any disease.
The information provided on this website is solely for informational and educational purposes and should not be considered as medical advice or a substitute for professional medical guidance.
ResearchChemical.com, its manufacturers, sellers, and distributors hold no liability for any consequences arising from the misuse, improper handling, or usage of these chemicals.
Please be aware that the sale and purchase of these chemicals may be subject to legal restrictions and regulations in some jurisdictions. It is the buyer’s responsibility to ensure compliance with all applicable laws and regulations.
1. Timms, M., Ganio, K., Forbes, G., Bailey, S., & Steel, R. (2019). An immuno polymerase chain reaction screen for the detection of CJC‐1295 and other growth‐hormone‐releasing hormone analogs in equine plasma. Drug testing and analysis, 11(6), 804-812
2. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
3. Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477.
4. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.
5. Pinyot, A., Nikolovski, Z., Bosch, J., Such-Sanmartín, G., Kageyama, S., Segura, J., & Gutiérrez-Gallego, R. (2012). Growth hormone secretagogues: out of competition. Analytical and bioanalytical chemistry, 402, 1101-1108.
6. Campbell, R. M., Bongers, J., & Felix, A. M. (1995). Rational design, synthesis, and biological evaluation of novel growth hormone-releasing factor analogues. Biopolymers: Original Research on Biomolecules, 37(2), 67-88.
7. Campbell, R. M., Stricker, P., Miller, R., Bongers, J., Liu, W., Lambros, T., … & Heimer, E. P. (1994). Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides, 15(3), 489-495.
8. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. doi: 10.1210/jc. 2005-1536.
9. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.
10. Ma, X., Lin, L., Yue, J., Pradhan, G., Qin, G., Minze, L. J., … & Sun, Y. (2013). Ghrelin receptor regulates HFCS-induced adipose inflammation and insulin resistance. Nutrition & diabetes, 3(12), e99-e99.
11. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective GH secretagogue. European Journal of Endocrinology. 1998 Oct;139(5):552-61. doi: 10.1530/eje.0.1390552.
12. Johansen, P. B., Nowak, J., Skjærbæk, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Ørskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113.
13. Vahl, N., Juul, A., Jørgensen, J. O., Ørskov, H., Skakkebæk, N. E., & Christiansen, J. S. (2000). Continuation of GH replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. The Journal of Clinical Endocrinology & Metabolism, 85(5), 1874-1881.
14. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., … & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of GH secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149.
15. Horvath, T. L., Castañeda, T., Tang-Christensen, M., Pagotto, U., & Tschop, M. H. (2003). Ghrelin as a potential anti-obesity target. Current Pharmaceutical Design, 9(17), 1383-1395.
16. Sjögren, K., Jansson, J. O., Isaksson, O. G., & Ohlsson, C. (2002). A model for tissue-specific inducible insulin-like growth factor-I (IGF-I) inactivation to determine the physiological role of liver-derived IGF-I. Endocrine, 19, 249-256.
17. D’Agostino, P. IGF-1 LR3: The rapid-acting GH alternative.
18. Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., & von Haehling, S. (2020). Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25-37.
19. Adeghate, E., & Ponery, A. S. (2004). Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters, 25(6), 403-406.
20. Andersen, N. B., Malmlöf, K., Johansen, P. B., Andreassen, T. T., Ørtoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research, 11(5), 266-272.
Please note that the above references provide evidence for the potential benefits of CJC 1295 DAC Peptide and Ipamorelin peptide as stated in the product description. For more in-depth information, kindly refer to these scholarly works.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Crafted to mimic the action of natural growth hormone-releasing hormone (GHRH), CJC-1295 DAC facilitates potent binding with growth hormone-releasing hormone receptors in the pituitary gland. With an extended half-life and fortified stability conferred by the Drug Affinity Complex (DAC), CJC-1295 DAC ensures sustained and reliable research, ideal for in-depth investigations into growth hormone dynamics and related research applications.
As a distinguished member of the Growth Hormone-Releasing Peptides (GHRP) family, Ipamorelin ignites research opportunities by stimulating the pituitary gland to release growth hormone. Its versatile action expands studies and research related to body fat management, skin elasticity enhancement, and energy level optimization, making it a crucial asset in diverse research pursuits.
By purchasing from ResearchChemical.com, you acknowledge and agree that you are acquiring Research Chemicals. These chemical substances are specifically designed for utilization in scientific and medical research endeavors.
It is essential to note that these research chemicals are intended exclusively for laboratory use. They are not sold for consumer use.
Please be advised that the statements made on this website have not been evaluated by the U.S. Food and Drug Administration (FDA). Furthermore, the products offered by this company are not intended to diagnose, treat, cure, or prevent any disease.
The information provided on this website is solely for informational and educational purposes and should not be considered as medical advice or a substitute for professional medical guidance.
ResearchChemical.com, its manufacturers, sellers, and distributors hold no liability for any consequences arising from the misuse, improper handling, or usage of these chemicals.
Please be aware that the sale and purchase of these chemicals may be subject to legal restrictions and regulations in some jurisdictions. It is the buyer’s responsibility to ensure compliance with all applicable laws and regulations.
1. Timms, M., Ganio, K., Forbes, G., Bailey, S., & Steel, R. (2019). An immuno polymerase chain reaction screen for the detection of CJC‐1295 and other growth‐hormone‐releasing hormone analogs in equine plasma. Drug testing and analysis, 11(6), 804-812
2. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
3. Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477.
4. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.
5. Pinyot, A., Nikolovski, Z., Bosch, J., Such-Sanmartín, G., Kageyama, S., Segura, J., & Gutiérrez-Gallego, R. (2012). Growth hormone secretagogues: out of competition. Analytical and bioanalytical chemistry, 402, 1101-1108.
6. Campbell, R. M., Bongers, J., & Felix, A. M. (1995). Rational design, synthesis, and biological evaluation of novel growth hormone-releasing factor analogues. Biopolymers: Original Research on Biomolecules, 37(2), 67-88.
7. Campbell, R. M., Stricker, P., Miller, R., Bongers, J., Liu, W., Lambros, T., … & Heimer, E. P. (1994). Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides, 15(3), 489-495.
8. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. doi: 10.1210/jc. 2005-1536.
9. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.
10. Ma, X., Lin, L., Yue, J., Pradhan, G., Qin, G., Minze, L. J., … & Sun, Y. (2013). Ghrelin receptor regulates HFCS-induced adipose inflammation and insulin resistance. Nutrition & diabetes, 3(12), e99-e99.
11. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective GH secretagogue. European Journal of Endocrinology. 1998 Oct;139(5):552-61. doi: 10.1530/eje.0.1390552.
12. Johansen, P. B., Nowak, J., Skjærbæk, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Ørskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113.
13. Vahl, N., Juul, A., Jørgensen, J. O., Ørskov, H., Skakkebæk, N. E., & Christiansen, J. S. (2000). Continuation of GH replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. The Journal of Clinical Endocrinology & Metabolism, 85(5), 1874-1881.
14. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., … & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of GH secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149.
15. Horvath, T. L., Castañeda, T., Tang-Christensen, M., Pagotto, U., & Tschop, M. H. (2003). Ghrelin as a potential anti-obesity target. Current Pharmaceutical Design, 9(17), 1383-1395.
16. Sjögren, K., Jansson, J. O., Isaksson, O. G., & Ohlsson, C. (2002). A model for tissue-specific inducible insulin-like growth factor-I (IGF-I) inactivation to determine the physiological role of liver-derived IGF-I. Endocrine, 19, 249-256.
17. D’Agostino, P. IGF-1 LR3: The rapid-acting GH alternative.
18. Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., & von Haehling, S. (2020). Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25-37.
19. Adeghate, E., & Ponery, A. S. (2004). Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters, 25(6), 403-406.
20. Andersen, N. B., Malmlöf, K., Johansen, P. B., Andreassen, T. T., Ørtoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research, 11(5), 266-272.
Please note that the above references provide evidence for the potential benefits of CJC 1295 DAC Peptide and Ipamorelin peptide as stated in the product description. For more in-depth information, kindly refer to these scholarly works.
Join our insider list for the latest research insights, product releases, and special offers—delivered straight to your inbox.
